The 8th Dermatology Drug Development Summit 2024 will take place in Boston, USA, bringing together over 130 biopharma and investment experts from leading organizations such as Johnson & Johnson, AbbVie, Sanofi, and LEO Pharma. From November 19-21, the summit promises three days of in-depth discussions and networking opportunities focused on advancing dermatology therapeutics.

This year's event highlights novel clinical data, immersive workshops on topics like Hidradenitis Suppurativa, JAK inhibitors, and indication expansion, along with specialized tracks for Discovery & Translational and Clinical & Commercialization experts.

SCARLETRED is proud to join the Summit as the lead and hosting partner. Our CEO, Harald Schnidar, MBA, PhD will be a featured speaker, presenting on "SCARLETRED AI: Breaking the Boundaries Between Human & Machine in Skin Drug Research." The presentation will delve into our groundbreaking Scarletred®Vision technology, demonstrating its impact on the analysis of skin conditions such as Rosacea and Hidradenitis Suppurativa.

For more information about the 8th Dermatology Drug Development Summit 2024 and to register, visit the event's official website here. Don't miss this opportunity to connect with leaders shaping the future of dermatology drug development!

‍